Melanoma is the deadliest form of commonly encountered skin cancer because of its rapid progression towards metastasis 1,2 . Although metabolic reprogramming is tightly associated with tumour progression, the effect of metabolic regulatory circuits on metastatic processes is poorly understood. PGC1α is a transcriptional coactivator that promotes mitochondrial biogenesis, protects against oxidative stress 3 and reprograms melanoma metabolism to influence drug sensitivity and survival 4,5 . Here, we provide data indicating that PGC1α suppresses melanoma metastasis, acting through a pathway distinct from that of its bioenergetic functions. Elevated PGC1α expression inversely correlates with vertical growth in human melanoma specimens. PGC1α silencing makes poorly metastatic melanoma cells highly invasive and, conversely, PGC1α reconstitution suppresses metastasis. Within populations of melanoma cells, there is a marked heterogeneity in PGC1α levels, which predicts their inherent high or low metastatic capacity. Mechanistically, PGC1α directly increases transcription of ID2, which in turn binds to and inactivates the transcription factor TCF4. Inactive TCF4 causes downregulation of metastasis-related genes, including integrins that are known to influence invasion and metastasis [6] [7] [8] . Inhibition of BRAF V600E using vemurafenib 9 , independently of its cytostatic effects, suppresses metastasis by acting on the PGC1α-ID2-TCF4-integrin axis. Together, our findings reveal that PGC1α maintains mitochondrial energetic metabolism and suppresses metastasis through direct regulation of parallel acting transcriptional programs. Consequently, components of these circuits define new therapeutic opportunities that may help to curb melanoma metastasis.
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Melanoma is the deadliest form of commonly encountered skin cancer because of its rapid progression towards metastasis 1,2 . Although metabolic reprogramming is tightly associated with tumour progression, the effect of metabolic regulatory circuits on metastatic processes is poorly understood. PGC1α is a transcriptional coactivator that promotes mitochondrial biogenesis, protects against oxidative stress 3 and reprograms melanoma metabolism to influence drug sensitivity and survival 4, 5 . Here, we provide data indicating that PGC1α suppresses melanoma metastasis, acting through a pathway distinct from that of its bioenergetic functions. Elevated PGC1α expression inversely correlates with vertical growth in human melanoma specimens. PGC1α silencing makes poorly metastatic melanoma cells highly invasive and, conversely, PGC1α reconstitution suppresses metastasis. Within populations of melanoma cells, there is a marked heterogeneity in PGC1α levels, which predicts their inherent high or low metastatic capacity. Mechanistically, PGC1α directly increases transcription of ID2, which in turn binds to and inactivates the transcription factor TCF4. Inactive TCF4 causes downregulation of metastasis-related genes, including integrins that are known to influence invasion and metastasis [6] [7] [8] . Inhibition of BRAF V600E using vemurafenib 9 , independently of its cytostatic effects, suppresses metastasis by acting on the PGC1α-ID2-TCF4-integrin axis. Together, our findings reveal that PGC1α maintains mitochondrial energetic metabolism and suppresses metastasis through direct regulation of parallel acting transcriptional programs. Consequently, components of these circuits define new therapeutic opportunities that may help to curb melanoma metastasis.
Whereas the landscape of genetic alterations and multiple driver mutations have been discovered in melanoma 10, 11 , less is understood about the genes that drive metastasis 2 . Nevertheless, it is thought that efficient metastasis requires the malignant cell to balance proliferation with invasion and migration 12, 13 . Elevated expression of the metabolic integrator and transcriptional coactivator peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC1α encoded by PPARGC1A) defines a subset of melanomas in which it promotes mitochondrial metabolism, protects against oxidative stress and enhances survival 4, 5 . Although high PGC1α expression is associated with worse prognosis in metastatic melanomas 4, 5 , reduced levels coincide with invasive or vertical growth in primary specimens (Fig. 1a) . Therefore, we investigated the effects of PGC1α on invasion and metastasis. Gene set enrichment analysis (GSEA) of expression data (GSE36879) 4 upon PGC1α knockdown in the poorly metastatic melanoma cell line A375P revealed coordinated upregulation of genes implicated in metastasis, including genes that control focal adhesion or extracellular matrix (ECM) interactions, integrins and components of the transforming growth factor-β (TGFβ ) and Wnt signalling pathways [14] [15] [16] [17] (Extended Data Fig. 1a, b) . In addition, PGC1α expression showed an inverse correlation with gene sets involved in melanoma metastasis (Extended Data Fig. 1c, d ). Upregulation of pro-metastatic genes following PGC1α suppression was confirmed by qPCR in PGC1α -positive melanoma cell lines ( Fig. 1b and Extended Data Fig. 2a-d) . Conversely, the increase in integrin transcripts was reversed upon ectopic PGC1α expression (Extended Data Fig. 2e , f). Targeting PGC1α using the CRISPR/Cas9 system led to similar gene expression changes (Extended Data Fig. 2g ).
Consistent with lower PGC1α expression during vertical growth and acquisition of the metastatic phenotype, the PGC1α -suppressed invasive and metastatic gene signature was associated with worse survival in patients with primary melanoma (Fig. 1c) . Changes in integrin expression upon PGC1α depletion were accompanied by activation of the downstream focal adhesion kinase (FAK) 18 ( Fig. 1d ) and increases in migration and invasion (Fig. 1e) . FAK inhibition blocked the enhanced migration induced by PGC1α depletion (Extended Data Fig. 2h-j) . Remarkably, silencing of PGC1α by either short hairpin RNA (shRNA) (Fig. 1f and Extended Data Fig. 3a, b) or CRISPR/Cas9 (Fig. 1g) converted these low-invasive, PGC1α -positive cells into highly metastatic entities as assessed by tail-vein injection experiments. To fully recapitulate the metastatic process in vivo, we used the human melanoma cell line MeWo in an orthotropic metastasis model 19 and found that, again, PGC1α suppression caused the subcutaneously implanted tumours to generate widespread disease (Fig. 1h) . Conversely, reconstitution of PGC1α in the PGC1α -negative cell lines A375 and A2058 decreased integrin expression ( Fig. 1i and Extended Data Fig. 3c, d ) and compromised their invasiveness in vitro and in vivo (Fig. 1j, k) . Together, these results indicate that PGC1α inhibits a pro-metastatic program in melanoma cells resulting in the suppression of invasion and metastasis.
Melanomas are highly heterogeneous and might switch between a proliferative and an invasive or metastatic phenotype 13 . Using MitoTracker (to label mitochondria) and FACS analysis, we found that melanoma cell lines with heightened PGC1α expression displayed heterogeneous mitochondrial mass (Fig. 2a) , which was dynamically regulated (Extended Data Fig. 4a) , and therefore could implicate alternate mitochondrial biogenesis and PGC1α function during phenotype switching. The sorted mitochondria-high (mito/PGC1α -high) population showed significantly higher expression of PGC1α and mitochondrial components, as well as lower expression of integrins, compared to the mitochondrialow (mito/PGC1α -low) population (Fig. 2a, b) . The PGC1α -low population showed enhanced migration in vitro and metastasis in vivo (Fig. 2c, d ). Compared to the non-migrating population, melanoma cells that had migrated through the transwell membrane expressed lower amounts of PGC1α and higher amounts of pro-metastatic transcripts ( ITGB3  ITGA3  ITGB5  ITGA4  ITGA10  ITGB3  ITGA3  ITGB5  ITGA4 Letter reSeArCH between PGC1α and metabolic heterogeneity with metastatic spread, we isolated circulating tumour cells (CTCs) from the blood of mice bearing subcutaneous PGC1α -positive MeWo tumours (Extended Data Fig. 4c ). Notably, these CTCs exhibited lower levels of PGC1α , but elevated integrins compared to the primary tumours (Fig. 2f) . However, in the corresponding lung metastases, which had formed from CTCs, PGC1α transcripts increased to similar levels as in the primary tumours (Fig. 2g) . Notably, restoration of PGC1α in lung metastases derived from PGC1α-knockdown cells enhanced tumour progression ( Fig. 2h and Extended Data Fig. 4d ), further demonstrating that increases in PGC1α in established metastases confer growth advantages similar to primary melanomas 4, 20 . In aggregate, these results indicate that melanoma cells display heterogeneous levels of PGC1α and mitochondria. The mito/PGC1α -low population expresses a prometastatic gene program, while the mito/PGC1α -high population drives a proliferation phenotype.
To assess the mechanisms by which PGC1α suppresses this prometastatic program, we surveyed genes that were upregulated upon PGC1α suppression for potential negative transcriptional regulators. We identified two Inhibitor of DNA binding (ID) proteins-ID2 and ID3-among the top differentially expressed genes. Levels of ID2 and ID3, but not ID1 or ID4, were reduced in melanoma cells upon PGC1α knockdown and increased by PGC1α (Extended Data Fig. 5a -c). Chromatin immunoprecipitation (ChIP) revealed that PGC1α was bound at the ID2 promoter, suggesting direct transcriptional regulation (Extended Data Fig. 5d ). Next, we depleted ID2 and ID3 in PGC1α -positive melanoma cells and found that suppression of ID2, but not ID3, increased integrin expression and downstream signalling ( Fig. 3a and Extended Data Fig. 5e-i ). Similar to PGC1α knockdown, ID2 depletion also strongly promoted migration, invasion and lung metastasis (Fig. 3b, c and Extended Data Fig. 5j ). To test whether ID2 mediates the repressive effect of PGC1α , we ectopically expressed ID2 in PGC1α -depleted cells (Extended Data Fig. 6a ). ID2 expression suppressed the induction of the pro-metastatic programs, invasion and metastasis enforced by PGC1α depletion (Fig. 3d-f and Extended Data Fig. 6b, c) . Similar results were observed when ID2 was ectopically expressed in PGC1α -negative melanoma cells (Extended Data Fig. 6d-f) . However, depletion of ID2, in contrast to PGC1α , did not alter glucose metabolism (Extended Data Fig. 6g ). Together, these data indicate that the ID2 inhibitor is a downstream target of PGC1α that suppresses pro-metastatic transcriptional programs without affecting PGC1α metabolic function.
ID2 functions as a transcriptional inhibitor through direct heterodimerization with basic helix-loop-helix (bHLH) factors, blocking ITGB3  ITGA3  ITGB5  ITGA4 ITGA10  LAMA4 INHBA  TGFBR3  TGFBI  TGFBR2 SMAD3 IL- binding to promoters [21] [22] [23] . To find bHLH factor(s) that could regulate integrin expression and metastasis driven by PGC1α suppression, we surveyed two different protein-protein interaction databases. BioGRID 24 displayed 34 unique ID2 interactors including the bHLH transcription factors TCF3, TCF4, MyoD and TCF12 (Extended Data Fig. 7a ). STRING 25 revealed three bHLH transcription factors (MYC, TCF3, TCF4) in the top 10 predicted partners (Extended Data  Fig. 7b ). Among these factors, only suppression of TCF4 was able to consistently reduce integrin expression in both A375P-shPGC1α and PGC1α -negative cells (Extended Data Fig. 7c-e) . Knockdown of TCF4 prevented the induction of integrins and FAK phosphorylation upon PGC1α or ID2 suppression (Fig. 3g and Extended Data Fig. 8a, b) . Co-immunoprecipitation showed that TCF4 binds to ID2 in A375P cells (Fig. 3h) . Consistent with this interaction, while the recruitment of TCF4 to promoters of integrins was increased upon PGC1α or ID2 knockdown, ectopic expression of ID2 blunted TCF4 recruitment (Extended Data Fig. 8c ). Ectopic expression of TCF4 was sufficient to induce integrin expression and signalling ( Fig. 3i and Extended Data Fig. 8d) , concordant with TCF4 recruitment to the integrin promoters (Fig. 3j) . TCF4 knockdown abrogated the enhanced migration and metastasis of cells in which PGC1α or ID2 was suppressed (Fig. 3k, l) and in PGC1α -negative cells (Extended Data Fig. 8e) . Notably, expression of PGC1α and TCF4 in cell lines and tumours was mutually exclusive (Extended Data Fig. 8f, g ), further supporting the opposing link between PGC1α and TCF4. Similar to ID2, manipulation of TCF4 levels did not alter cellular metabolism (Extended Data Fig. 8h ), indicating that the effects of PGC1α on metastasis are separable from its metabolic functions. Collectively, these data show that TCF4 is required for the pro-metastatic transcriptional program which leads, upon PGC1α suppression, to increased invasion and metastasis.
PLX4032 (vemurafenib), a BRAF V600E inhibitor, has been shown to increase PGC1α expression in melanoma cells harbouring this mutation 5, 9, 26 . Based on the results described here, PLX4032 could inhibit metastasis by acting on the PGC1α transcriptional axis. Treatment of BRAF V600E melanoma cells with PLX4032 or MEK inhibitors strongly induced PGC1α and ID2 expression (Fig. 4a) , and reduced levels of most integrins tested (Fig. 4b, c and Extended Data Fig. 9a) . Consistently, PLX4032 increased the recruitment of PGC1α to the ID2 promoter (Extended Data Fig. 9b ) and strongly induced the interaction between ID2 and TCF4 (Fig. 4d) , decreasing TCF4 promoter occupancy at four integrin genes (Fig. 4e) . Despite FAK activation, measured as phospho-Y397-FAK levels, which was slightly inhibited upon MAPK blockage (Fig. 4c) , PLX4032 was able to repress melanoma invasion in vitro and metastasis in vivo, which was largely reversed by 
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PGC1α or ID2 depletion (Fig. 4f, g and Extended Data Fig. 9c) . Within the time frame of the in vitro assay (24 h), PLX4032 did not decrease cell growth (Extended Data Fig. 9d ) and the dose of PLX4032 used in mice (1 mg kg −1 ) was lower than the dose used to induce tumour regression 27 . Together, these data indicate that PLX4032 can suppress invasion and metastasis independent of its cytostatic effects. PLX4032-induced inhibition of metastasis is mediated, at least in part, through transcriptional activation of PGC1α .
Our results overall indicate that the metabolic transcriptional coactivator PGC1α is an apical regulator of melanoma progression through protection against oxidative stress, which confers survival and proliferative advantages 4, 5, 20 , and suppression of cell motility, cell-cell interaction, adhesion and invasion that promotes metastatic drive. Notably, PGC1α expression is inversely correlated with invasive growth in local disease, whereas in metastatic melanomas it is associated with worse outcomes. Although PGC1α status defines a subset of melanomas with specific characteristics, its heterogeneous expression within tumours allows different proliferative or invasive abilities (Fig. 4h) . We argue that the heterogeneity of PGC1α levels within melanomas reflects a dualistic nature of PGC1α function-promoting growth and survival of tumours, whilst suppressing metastatic spread. This heterogeneity might be important during melanoma progression through changes in PGC1α in response to different signals including nutrients, and switching between survival-proliferation and invasion-metastasis. From a therapeutic standpoint, independent of the cytotoxic/cytostatic effects, our results extend the clinical benefits of BRAF Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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Reagents and antibodies. PLX4032, PD98059, AZD6244 and PF-573228 were purchased from Selleck Chemicals. The siRNAs against TCF4 (sc-61657), c-Myc (sc-29226), TCF3 (sc-36618) or TCF12 (sc-35552) were purchased from Santa Cruz Biotechnology. Antibodies against ITGA4, ITGA5, ITGB1, ITGB3, ITGB4, ITGB5, FAK, c-Myc, TCF12, ERK1/2, pERK1/2 and Porin were purchased from Cell Signaling Technology; p-FAK (Y397) antibodies were from Cell Signaling and Thermo Fisher Scientific, ID2 antibodies were from Cell Signaling, Santa Cruz Biotechnology and Thermo Fisher; tubulin, V5, HMB45, COX5 A, NDUFS4 and NDUFA9 antibodies were from Abcam; TCF4 antibodies were from Abnova and Santa Cruz; and PGC1α antibodies were from Santa Cruz and Millipore. GSEA analysis. The GSEA software v2.0 (http://www.broadinstitute.org/gsea) 30 was used to perform the GSEA analysis. In all the analysis, the KEGG gene sets were used. The values of the 219195_at probe (corresponding to PPARGC1A) were used as phenotype. For the analysis of the CCLE data set, the gene expression data was downloaded from the CCLE portal (wwww.broadinstitute.org/CCLE) and the data from 61 melanoma cell lines were used in the analysis. The GSEA default parameters were used with the exception that Pearson correlation was computed to rank the genes for the analysis of the CCLE data and permutation was changed to gene set for the analysis of the GSE36879 data set. Expression Data set Analysis. Published data sets GSE3189 31 and GSE12391 32 with associated pathological stages for each sample as Invasive/Vertical or Superficial/ Radial were analysed for relative deviation from median-normalized PGC1α intensities (linear) within each data set (significance based on 2-sample, 2-sided t-test statistics). To examine the enrichment of the PGC1α -regulated metastasis/invasion signature genes (ITGA3, ITGA4, ITGA10, ITGB3, ITGB5, CAV1, CAV2, ACTN2, LAMA4A, COL4A1, INHBA, TGFBI, TGFBR3, TGFBR2, SMAD3, SMAD7, IL8, IL11, LEF1, TCF7L2, DKK3, PPP3CA and SFRP1), we performed ssGSEA projections 33 to yield a percentile-based normalized enrichment score within each of GSE3189 and GSE12391, which were used to combine the data sets (2-sample, 2-sided t-test statistics). The association between primary melanoma survival and PGC1α -regulated metastasis/invasion signature was based on ssGSEA for signature closeness within GSE57715 and calculation of log-rank survival.
For the analysis of PGC1α and TCF4 gene expression, data obtained from the TCGA skin cutaneous melanoma data set 34 consisting of 471 samples with RNA-seq data was downloaded from the cBioPortal 35, 36 (www.cbioportal.org). Data were represented as Z-scores of RNA-seq V2 RSM. The dotted lines denote Z-scores of 0. Samples were classified as expressing if Z-score > 0 and a mutually exclusivity report from the cBioPortal was generated. Generation of lentiviral vectors. The pDONR223-LacZ entry control vector was purchased from Addgene (25893) and the pLX304-LacZ control vector was generated using LR clonase II (Invitrogen). The V5-tagged pLX304-ID2 and -TCF4 vectors were provided by the Marc Vidal Laboratory at Dana-Farber Cancer Institute. Luciferase-expressing FUW-Luc was provided by A. Kung and the pMSCVLuciferase-hygro plasmid was purchased from Addgene. Full-length PGC1α was amplified by KOD polymerase (F: GCTTGGGACATGTGCAGCGAA and R: TTACCTGCGCAAGCTTCTCTGAGC), and then the PCR product was ligated into pDONR223 by BP reaction. PGC1α expressing destination vectors (pLX304 for constitutive expression and pInducer20 37 for doxycycline-inducible expression) were generated by LR reaction with entry vector (pDONR223-PGC1α ). Cell culture, siRNA transfection, shRNA transduction and CRISPR generation. Melanoma cells were obtained from ATCC and their authentication was confirmed by either DNA fingerprinting with small tandem repeat (STR) profiling or in-house PCR testing of melanoma marker genes and BRAF mutation status. Mycoplasma contamination was tested negative in-house with the PCR Mycoplasma Detection Kit (Lonza). Melanoma cells were cultured in high-glucose DMEM containing 10% FBS. For detachment culture conditions, cells were plated on plates coated with poly-2-hydroxy methacrylate (poly-HEMA). Lentiviruses encoding shRNAs or cDNAs were produced in HEK293T cells with packaging vectors (pMD2G and psPAX2) using Polyfect (Qiagen). pLKO.1 vector expressing a scramble sequence, as listed in the Supplementary Information, was used as control (shScr). Lentiviruses particles were collected 48 h post-transfection and used to infect melanoma cells in the presence of 8 μ g/ml polybrene. Infected cells were selected with 2 μ g/ml of puromycin or 7 μ g/ml blasticidin for 4 days before experiments. siRNA transfection was performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Guide-RNAs were cloned into pLX-sgRNA (Addgene #50662 for PGC1α ) or lentiCRISPR (Addgene #52961 for ID2). The respective empty vector lacking the sgRNA sequence was used as control (sgCtrl). Cells were subsequently infected with lentiviruses encoding Cas9 (pCW-Cas9, Addgene #50661) and sgRNAs followed by selection with respective antibiotics as described above, and 1 μ g/ml of doxycycline for 7 days. Western Blot. Cells were lysed in a buffer containing 1% IGEPAL, 150 mM NaCl, 20 mM HEPES (pH7.9), 10 mM NaF, 0.1 mM EDTA, 1 mM sodium orthovanadate and 1× protease inhibitor cocktail. Protein concentration was quantified using the BCA protein concentration assay kit (Pierce). Cell lysates were electrophoresed on SDS-polyacrylamide gels and transferred to Immobilon-P membranes (Millipore). Membranes were incubated with primary antibodies in 5% bovine serum albumin containing 0.05% Tween-20 overnight at 4 °C. The membrane was then incubated with HRP-conjugated secondary antibody for 1 h at room temperature, and visualized using an ECL Prime (GE Healthcare). Quantitative real-time PCR. Total RNA was isolated with Trizol (Invitrogen) by Direct-zol RNA MiniPrep kit (Zymo Research), and 2 μ g of total RNA was used for cDNA synthesis using a high capacity cDNA reverse transcription kit (Applied Biosystems). qPCR was carried out using SYBR Green PCR Master Mix (Applied Biosystems). Experimental Ct values were normalized to 36B4 where not otherwise indicated and relative mRNA expression was calculated. Sequences for all the primers are provided in the Supplementary Information.
For PGC1α overexpression by adenovirus, A375P-shPGC1α and A375 cells were infected with adenoviruses expressing GFP or Flag-PGC1α for 36 h, followed by qPCR. PGC1α targets such as GSTM4 and COX5 A were used as positive controls. For inhibitor treatment, cells were incubated with indicated concentrations of inhibitors for 6 h and mRNAs were analysed by qPCR. For the RNA from migratory and non-migratory cells, migration of the A375P and G361 cells was initiated as described below. The non-migratory cells in suspension in the upper chambers were collected by centrifugation and resuspension in lysis buffer from the Cells-to-cDNA II kit (Invitrogen). The migratory cells were collected by directly applying the lysis buffer to the membrane, following the wash and clearing of the non-migratory cells in the upper chambers. 18S rRNA was used as internal control. For cells from paraffin-embedded tissue sections, Pinpoint Slide RNA Isolation System II (Zymo Research) was used to extract RNAs. Cell Sorting. Cells with different mitochondrial contents were sorted based on the labelling of MitoTracker Green (Invitrogen). Briefly, MitoTracker Green was spiked in the medium of 100% confluent melanoma cells at the final concentration of 75 nM, and incubated with the cells for 20 min, followed by FACS sorting at DFCI Flow Cytometry Core. The top 10% cell population with the highest mitochondrial contents (mito/PGC1α -high) and the bottom 10% cell population with the lowest mitochondrial contents (mito/PGC1α -low) were collected for qPCR, western blot, migration assay (1 × 10 5 per well overnight) and metastasis assay. For the circulating tumour cells, whole blood of the tumour-bearing mice was collected by cardiac perfusion with PBS containing 0.5 mM EDTA. After red blood cell lysis, the pelleted cells were stained with anti-mouse CD31 and CD45, along with anti-human HLA (eBioscience, as depicted in Extended Data Fig. 4c ). The CD31 − CD45 − hHLA + cells were directly sorted into RNAprotect Cell Reagent (Qiagen), and then converted into cDNA using the Cells-to-cDNA II kit. The primary tumours were subjected to enzymatic digestion for single cell suspension and FACS sorting to make them equivalent controls. qPCR was performed with SYBR Green, following the unbiased, target-specific preamplification of cDNA using SsoAdvanced PreAmp Supermix (BioRad). Experimental Ct values were normalized to 18S rRNA, and relative mRNA expression was calculated. Glucose consumption and lactate production assays. Lactate and glucose assay kits (BioVision Research Products) were used to measure extracellular lactate and glucose, following manufacturer's instructions. Briefly, equal number of cells were seeded in 6-well plates and cultured in Phenol-Red-free DMEM for 24 h or 36 h. Cultured medium was then mixed with the reaction solution. Lactate and glucose levels were measured at 450 nm and 570 nm, respectively, using a FLUO star Omega plate reader. Values were normalized to cell number. In vivo metastasis assays. Melanoma cell lines were lifted by 0.5 mM EDTA in PBS and washed with 1 × PBS. For the intravenous injection, a total of 3 × 10 5 (A375) or 1 × 10 6 (G361 and MeWo) or 2 × 10 6 (A375P and FACS-sorted MeWo) cells in 0.2 ml of DMEM were injected into the tail veins of 6-week-old male nude mice. No randomization or blinding techniques were applied in this study. To assess the degree of tumour formation in the lung, bioluminescence imaging of living mice was performed on a Xenogen IVIS-50TM imaging system equipped with an isoflurane (1-3%) anaesthesia system and a temperature-controlled platform 19 , three weeks (G361 and MeWo) or four weeks (A375 and A375P) post-injection. For the doxycycline-induction experiment, upon detection of lung metastasis following tail-vein implantation, PGC1α expression was induced by feeding mice with a chow or doxycycline-containing diet (200 mg/kg, Harlan Laboratories) for one week. For the orthotopic metastasis model, 1 × 10 6 cells were injected subcutaneously into one side of 6-week-old male NOD/SCID mice, with two injections per animal, followed by surgical tumour removal when the subcutaneous tumours reached 2 mm in diameter. Metastasis was monitored by in vivo imaging at 8-10 weeks post-surgery. After the measurement of bioluminescence, animals were killed and the lungs were removed. Collected lung tissues were fixed in 10% buffered formalin solution (Sigma-Aldrich) overnight. Fixed tissues were stained with haematoxylin and eosin (H&E) or antibodies against p-FAK-Y397 (Invitrogen) or HMB45
Letter reSeArCH 3 ) or WM115 (4 × 10 3 ) cells in 0.1 ml of FBS-free medium were seeded into the upper chamber of an 8 μ M matrigel coated chamber (BD Bioscience) and incubated for 16 h if not otherwise indicated. Specifically, for the migration and invasion assays on sorted cells (Fig. 2c ) or A375P cells with ID2 knockdown (Fig. 3b) , 1 × 10 5 cells were seeded and incubated for 24 h. Cells that had migrated and invaded through the matrigel were then fixed and stained with H&E if not otherwise indicated. The membrane attached with migrated and invaded cells was placed on a glass slide and total cell numbers from three or four random fields under 20-40× magnifications were quantified with an Olympus IX51 or a Nikon 80i Upright microscope, by counting cells on 20-50% of one field area and extrapolated to 100% of the field 17 . Specifically for the experiments with FAK inhibitor, shScr or shPGC1α stably expressing cells (A375P 1 × 10 5 per well, G361 2.5 × 10 4 per well) were cultured in transwell chambers with either DMSO or indicated concentration of PF-573228, followed by staining with Crystal Violet and quantification after migration for 24 h. For the experiments with PLX4032, cells were incubated with DMSO or 1 μ M PLX4032 for 10 h in matrigel-coated transwell chambers, followed by quantification. Co-immunoprecipitation and chromatin immunoprecipitation assays. Nuclear lysates were incubated with specific antibodies overnight at 4 °C, followed by precipitation with protein G Dynabeads (Invitrogen) at 4 °C for 2 h. For Fig. 3h , nuclear lysates from V5− ID2 stably-expressing A375P cells were subjected to co-IP with 1 μ g ID2 antibody (C-20, Santa Cruz Biotechnology), followed by western blot with TCF4 (M03, Abnova) and ID2 (4E12G5, Thermo Scientific); for Fig. 4d , 10 mg of nuclear lysates from A375P cells treated with DMSO or 1 μ M PLX4032 for 16 h were subjected to co-IP with 4 μ g ID2 antibody (C-20) . ChIP was performed with the MilliPore ChIP Kit with slight modification. Following sonication, nuclear lysates were precleared with protein A/G-Dynabeads (Invitrogen) for 1 h. Equal amounts of precleared lysates were incubated with IgG or gene-specific antibodies (PGC1α 4C1.3 from Millipore, or PGC1α H-300, and TCF4 K-15 from Santa Cruz Biotechnology) overnight, followed by precipitation with protein A/G-Dynabeads for 2 h. qPCR with SYBR Green was performed to quantify the promoter occupancy. For Fig. 4e , A375P cells stably expressing V5-TCF4 were cultured with PLX4032 at 5 μ M for 16 h and followed by ChIP and qPCR. Cell growth and survival assays. A ToxiLight Non-destructive Cytotoxicity BioAssay Kit (Lonza) was used to quantify the cytotoxic effects of the indicated compounds according to the manufacturer's instruction. The measurement of dead cells in the DMSO group was set as 1, and was used to normalize other treatment groups (Extended Data Fig. 2j ). For the cell growth assay with PLX4032 (Extended Data Fig. 9d ), cells were cultured with DMSO or PLX4032 for the indicated time under either attachment or detachment conditions, followed by cell counting with a haemocytometer. For detachment culture conditions, cells were plated on tissue culture plates coated with poly-HEMA. Statistics. No statistical methods were used to predetermine sample size. All statistics are described in figure legends. In general, for two experimental comparisons, a two-tailed unpaired Student's t-test was used unless otherwise indicated. For multiple comparisons, one-way ANOVAs were applied. When cells were used for experiments, three replicates per treatment were chosen as an initial sample size. All n values defined in the legends refer to biological replicates. If technical failures such as tail-vein injection failure or inadequate intraperitoneal injection occurred before collection, those samples were excluded from the final analysis. Statistical significance is represented by asterisks corresponding to * P < 0.05, * * P < 0.01 and * * * P < 0.005. Figure 4 | Melanoma cells contain heterogeneous levels of mitochondria and PGC1α. a, The mitochondrial content in melanoma cells is dynamically regulated. After 24 h in culture, the sorted mito-high and -low A375P subpopulations re-establish normal mitochondrial content distribution. b, Within the PGC1α -positive G361 line, the cells with higher migratory ability express lower PGC1α and elevated prometastatic genes. Values represent mean ± s.d. of triplicates; * P < 0.05 and * * P < 0.01 by Student's t-test. c, Isolation of circulating tumour cells (CTCs) from a tumour-bearing mouse. Two months post-injection, when the subcutaneous MeWo tumours became detectable, whole blood was collected by cardiac perfusion, followed by FACS based on surface protein staining with mouse CD31 and CD45 to exclude endothelial cells and lymphocytes and human HLA abc to purify human tumour cells. The primary subcutaneous tumours were enzymatically digested into single-cell suspension and subjected to the same sorting strategy. d, Gene expression in A375P melanoma cells after PGC1α induction. Values represent mean ± s.d. of independent biological triplicates; * P < 0.05, * * * P < 0.01 and * * * P < 0.001 versus shScr/DMSO; # P < 0.05 and ## P < 0.01 versus shPGC1α /DMSO by Student's t-test.
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